Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.93
(2.24%)
USD 0.93
(2.24%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 209.03 Million USD | -16.5% |
| 2022 | 250.33 Million USD | 7.78% |
| 2021 | 232.25 Million USD | 62.49% |
| 2020 | 142.94 Million USD | 18.99% |
| 2019 | 120.12 Million USD | 150.28% |
| 2018 | -238.89 Million USD | -208.71% |
| 2017 | -77.38 Million USD | -49.19% |
| 2016 | -51.87 Million USD | 49.19% |
| 2015 | -102.08 Million USD | 39.72% |
| 2014 | -169.37 Million USD | 32.79% |
| 2013 | -252 Million USD | -246.34% |
| 2012 | -72.76 Million USD | -10.01% |
| 2011 | -66.14 Million USD | -8.85% |
| 2010 | -60.76 Million USD | 16.5% |
| 2009 | -72.77 Million USD | -30.13% |
| 2008 | -55.92 Million USD | 2.94% |
| 2007 | -57.61 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 11.45 Million USD | -74.2% |
| 2024 Q2 | 27.04 Million USD | 136.05% |
| 2023 Q3 | 40.02 Million USD | 103.7% |
| 2023 Q4 | 44.41 Million USD | 10.96% |
| 2023 Q1 | 60.09 Million USD | -12.09% |
| 2023 Q2 | -1.08 Billion USD | -1902.32% |
| 2023 FY | 209.03 Million USD | -16.5% |
| 2022 Q2 | 55.65 Million USD | -3.79% |
| 2022 Q3 | 68.47 Million USD | 23.03% |
| 2022 Q4 | 68.36 Million USD | -0.16% |
| 2022 FY | 250.33 Million USD | 7.78% |
| 2022 Q1 | 57.84 Million USD | 2.22% |
| 2021 Q4 | 56.59 Million USD | -13.16% |
| 2021 FY | 232.25 Million USD | 62.49% |
| 2021 Q2 | 65.09 Million USD | 43.39% |
| 2021 Q1 | 45.39 Million USD | -11.65% |
| 2021 Q3 | 65.17 Million USD | 0.11% |
| 2020 FY | 142.94 Million USD | 18.99% |
| 2020 Q3 | 45.61 Million USD | 39.44% |
| 2020 Q2 | 32.71 Million USD | 147.32% |
| 2020 Q1 | 13.22 Million USD | -73.33% |
| 2020 Q4 | 51.38 Million USD | 12.64% |
| 2019 Q1 | -54.37 Million USD | -1006.96% |
| 2019 Q3 | 65.88 Million USD | 205.36% |
| 2019 Q4 | 49.59 Million USD | -24.73% |
| 2019 FY | 120.12 Million USD | 150.28% |
| 2019 Q2 | 21.57 Million USD | 139.68% |
| 2018 Q3 | -169.09 Million USD | -323.59% |
| 2018 FY | -238.89 Million USD | -208.71% |
| 2018 Q1 | -35.86 Million USD | -257.56% |
| 2018 Q2 | -39.92 Million USD | -11.3% |
| 2018 Q4 | 5.99 Million USD | 103.55% |
| 2017 Q4 | 22.76 Million USD | 217.14% |
| 2017 Q3 | -19.43 Million USD | 52.61% |
| 2017 FY | -77.38 Million USD | -49.19% |
| 2017 Q2 | -41.01 Million USD | -3.29% |
| 2017 Q1 | -39.7 Million USD | -530.24% |
| 2016 FY | -51.87 Million USD | 49.19% |
| 2016 Q4 | -6.3 Million USD | 77.73% |
| 2016 Q3 | -28.28 Million USD | -84.7% |
| 2016 Q2 | -15.31 Million USD | -678.2% |
| 2016 Q1 | -1.96 Million USD | 66.23% |
| 2015 Q4 | -5.82 Million USD | 77.75% |
| 2015 Q2 | -42 Million USD | -49.67% |
| 2015 Q3 | -26.18 Million USD | 37.67% |
| 2015 Q1 | -28.06 Million USD | 15.27% |
| 2015 FY | -102.08 Million USD | 39.72% |
| 2014 Q1 | -44.38 Million USD | 5.03% |
| 2014 Q3 | -36.73 Million USD | 33.35% |
| 2014 Q4 | -33.12 Million USD | 9.84% |
| 2014 FY | -169.37 Million USD | 32.79% |
| 2014 Q2 | -55.11 Million USD | -24.18% |
| 2013 FY | -252 Million USD | -246.34% |
| 2013 Q2 | -59.88 Million USD | 32.59% |
| 2013 Q3 | -56.55 Million USD | 5.56% |
| 2013 Q4 | -46.73 Million USD | 17.35% |
| 2013 Q1 | -88.83 Million USD | -102.35% |
| 2012 Q1 | -35.63 Million USD | -406.77% |
| 2012 FY | -72.76 Million USD | -10.01% |
| 2012 Q3 | 47.6 Million USD | 216.59% |
| 2012 Q2 | -40.83 Million USD | -14.59% |
| 2012 Q4 | -43.9 Million USD | -192.21% |
| 2011 Q2 | -18.95 Million USD | -2.21% |
| 2011 Q4 | -7.03 Million USD | 67.47% |
| 2011 FY | -66.14 Million USD | -8.85% |
| 2011 Q3 | -21.61 Million USD | -14.06% |
| 2011 Q1 | -18.54 Million USD | -44.92% |
| 2010 Q4 | -12.79 Million USD | 20.85% |
| 2010 FY | -60.76 Million USD | 16.5% |
| 2010 Q2 | -17.31 Million USD | -6.72% |
| 2010 Q1 | -16.22 Million USD | 32.76% |
| 2010 Q3 | -16.16 Million USD | 6.66% |
| 2009 FY | -72.77 Million USD | -30.13% |
| 2009 Q1 | -18.57 Million USD | -10.54% |
| 2009 Q2 | -18.57 Million USD | -0.04% |
| 2009 Q3 | -8.28 Million USD | 55.39% |
| 2009 Q4 | -24.13 Million USD | -191.24% |
| 2008 Q4 | -16.8 Million USD | 0.0% |
| 2008 FY | -55.92 Million USD | 2.94% |
| 2007 FY | -57.61 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 234.374% |
| Theratechnologies Inc. | -10.62 Million USD | 2067.027% |
| Safety Shot Inc | -12.18 Million USD | 1815.639% |
| Cosmos Health Inc. | -21.83 Million USD | 1057.51% |
| Cronos Group Inc. | -81.37 Million USD | 356.878% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 633.895% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -1568.95% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 6027.116% |
| ProPhase Labs, Inc. | -21.61 Million USD | 1067.177% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 4546.628% |
| Dynavax Technologies Corporation | -37.02 Million USD | 664.535% |
| Radius Health, Inc. | -3.92 Million USD | 5425.758% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 8410.853% |
| Alvotech | -354.86 Million USD | 158.907% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 4468.295% |
| Alpha Teknova, Inc. | -35.56 Million USD | 687.791% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 231.155% |
| SCYNEXIS, Inc. | 72.66 Million USD | -187.655% |
| Harrow Health, Inc. | 580 Thousand USD | -35940.69% |
| Biofrontera Inc. | -22.67 Million USD | 1021.797% |
| DURECT Corporation | -36.88 Million USD | 666.739% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 4067.28% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -345.032% |
| OptiNose, Inc. | -22.74 Million USD | 1018.92% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -1554.813% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 1484.161% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 3465.675% |
| SIGA Technologies, Inc. | 83.62 Million USD | -149.98% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -2140.231% |
| Shineco, Inc. | -17.06 Million USD | 1324.877% |
| Phibro Animal Health Corporation | 53.31 Million USD | -292.077% |
| Procaps Group S.A. | 52.32 Million USD | -299.503% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 2552.611% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 4513.09% |
| Viatris Inc. | 766.2 Million USD | 72.718% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 4468.295% |
| Rockwell Medical, Inc. | -6.67 Million USD | 3233.973% |
| Incannex Healthcare Limited | -30.04 Million USD | 795.836% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 4078.607% |
| Tilray Brands, Inc. | -174.74 Million USD | 219.623% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | -25.2% |
| PetIQ, Inc. | 60.01 Million USD | -248.306% |
| Silver Spike Investment Corp. | 7.34 Million USD | -2747.859% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 16.686% |
| Journey Medical Corporation | -2.07 Million USD | 10183.743% |
| Alimera Sciences, Inc. | -1.47 Million USD | 14310.469% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 1635.069% |
| Assertio Holdings, Inc. | -243.53 Million USD | 185.834% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 3647.565% |
| Embecta Corp. | 221.5 Million USD | 5.627% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1142.571% |
| Procaps Group, S.A. | 38.97 Million USD | -436.361% |
| PainReform Ltd. | -9.58 Million USD | 2281.093% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 251.641% |
| Hempacco Co., Inc. | -8.81 Million USD | 2472.099% |
| Talphera, Inc. | -16.88 Million USD | 1337.705% |
| Pacira BioSciences, Inc. | 87.67 Million USD | -138.421% |
| Alvotech | -354.86 Million USD | 158.907% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 42.674% |
| Kamada Ltd. | 10.06 Million USD | -1977.067% |
| Indivior PLC | -4 Million USD | 5325.9% |
| Currenc Group, Inc. | -6.64 Million USD | 3245.392% |
| Evoke Pharma, Inc. | -7.43 Million USD | 2913.068% |
| Flora Growth Corp. | -50.35 Million USD | 515.133% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1142.571% |
| Evolus, Inc. | -49.23 Million USD | 524.585% |
| HUTCHMED (China) Limited | 18.37 Million USD | -1037.611% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | -6.117% |
| Akanda Corp. | -10.05 Million USD | 2179.676% |